Cardiac AI: Where Clinical Evidence Drives Billion-Dollar Innovation

The healthcare AI field is awash with claims of innovation, but for discerning investors, the true measure of a company’s potential lies not in its marketing prowess, but in its ability to navigate the stringent gauntlet of clinical validation and regulatory clearance. This distinction is particularly acute in cardiovascular AI, where patient safety and diagnostic accuracy are paramount. We challenge the notion that innovation is solely about novel algorithms. Instead, we contend that clinical evidence is the primary moat in healthcare AI, defining genuine market leadership and investment-worthy ventures.

Benchmarking Success: Clinical Evidence as the Primary Moat

When evaluating the “most innovative AI cardiovascular companies,” the benchmarks must extend far beyond technical sophistication. Innovation in this sector is intrinsically tied to demonstrating efficacy, safety, and utility in real-world clinical settings, a process rigorously scrutinized by regulatory bodies and peer-reviewed journals. Without this foundational evidence, even the most advanced AI remains a theoretical promise, not a commercial reality with clear reimbursement pathways. Our analysis, grounded in regulatory filing analysis and clinical database interrogation, reveals a clear hierarchy. Companies that prioritize strong clinical trials and secure FDA clearances are not merely demonstrating compliance. They are building an unassailable competitive advantage. This approach de-risks the investment, clarifies the total addressable market (TAM), and provides a tangible pathway to commercialization and, in the end, exit multiples.

A Comparative Lens: Cleerly, Eko Health, and Ultromics

To illustrate this framework, we examine three prominent players in the cardiovascular AI space: Cleerly, focusing on coronary artery disease (CAD). Eko Health, with its digital stethoscopes and AI detection capabilities. And Ultromics, a leader in echocardiography AI. While each addresses a critical unmet need, their approaches to clinical validation and regulatory milestones offer instructive lessons for investors.

Cleerly: Precision in Coronary Artery Disease

Cleerly has positioned itself as an AI-native company, using advanced AI to quantify and characterize coronary plaque from CT angiography (CTA) scans. Their innovation lies in moving beyond traditional stenosis assessment to provide a more complete, phenotype-based understanding of CAD. From an investor perspective, their strength is rooted in a growing body of clinical trial publications demonstrating the predictive power of their AI for major adverse cardiac events. Cleerly clinical trial publication data Their FDA 510(k) clearances for their various software modules, including Cleerly LABS v2.0 cleared in March 2025, and Cleerly ISCHEMIA cleared in January 2024, underscore a commitment to regulatory de-risking. Cleerly also received FDA Breakthrough Device Designation for its Coronary Artery Disease (CAD) Staging System in March 2024. The consistent expansion of their cleared indications reflects a systematic approach to validating their SaMD. The ability to demonstrate improved patient outcomes and guide therapeutic decisions based on AI-driven insights is a powerful commercial predictor, creating a data moat that is difficult for competitors to replicate without similar rigorous clinical investment. Cleerly ISCHEMIA is billable under Category I CPT code 75580, effective January 1, 2024, and a Category I CPT code 75577 for plaque analysis from CCTA was approved, effective January 1, 2026. Major commercial payers, including Aetna, UnitedHealthcare, and Cigna, now provide coverage for Cleerly LABS plaque analysis.

Eko Health: Augmenting Auscultation with AI

Eko Health exemplifies innovation in point-of-care diagnostics, integrating AI into digital stethoscopes to detect heart murmurs and atrial fibrillation (AFib). Their wedge product, the digital stethoscope, is a gateway for their AI algorithms. The value proposition here is clear: democratizing early detection of critical cardiac conditions, potentially reducing diagnostic delays and improving patient access to care. Eko’s regulatory strategy has focused on securing FDA 510(k) clearances for its AI algorithms, such as those for detecting AFib and heart murmurs. They received FDA clearance for their Low EF detection AI in April 2024, and their EFAST algorithm, the first FDA-cleared cardiac foundation model, was cleared in September 2025, indicated for structural heart murmurs and AFib. This regulatory achievement is important, as it transforms their AI from a research tool into a deployable medical device. Their innovation is further validated by peer-reviewed studies demonstrating the accuracy of their algorithms in diverse clinical settings, including the TRICORDER study published in The Lancet in January 2026, which showed significant gains in early cardiac disease detection with AI-assisted stethoscope exams. For investors, Eko’s model highlights the importance of integrating AI into existing clinical workflows with demonstrable clinical utility and a clear regulatory pathway. Eko Health was granted a Category III CPT code for its SENSORA platform, effective July 1, 2025, with CMS assigning an OPPS payment in 2025. Eko Health FDA 510(k) clearances

Ultromics: AI-Powered Echocardiography Analysis

Ultromics stands out in the echocardiography space, applying AI to automate and standardize the interpretation of echo images, particularly for conditions like heart failure and valvular disease. Their innovation addresses the challenges of variability in human interpretation and the time-consuming nature of manual analysis. Ultromics’ AI provides quantitative assessments, which can enhance diagnostic precision and consistency. The company has secured multiple FDA 510(k) clearances for its various AI-powered solutions, including four FDA clearances and two FDA Breakthrough Device Designations. Notably, Ultromics received FDA Breakthrough Device clearance for EchoGo® Amyloidosis in late 2024, which also achieved marketing authorization in November 2024. Their EchoGo Heart Failure device received 510(k) clearance in December 2022. Their clinical evidence often involves demonstrating agreement with expert human readers and, increasingly, showing improved diagnostic accuracy or efficiency, with EchoGo® Heart Failure demonstrating potential for earlier HFpEF identification. Ultromics’ strategy underlines the critical need for cardiac AI to not just replicate, but demonstrably improve upon, current standards of care. Their commitment to building a QMS compliant with ISO 13485 further signals a mature approach to product development and regulatory readiness. Ultromics has secured a Category III CPT code (0932T) for EchoGo® Heart Failure from AMA, effective January 1, 2025, and it also has NTAP coverage (XXE2X19) for hospital inpatient settings, effective October 1, 2023. EchoGo® Amyloidosis is covered under Category III CPT Code 0932T (effective January 1, 2025) for outpatient settings and NTAP XXE2X19 for inpatient use. Ultromics FDA 510(k) clearance documents

Benchmarking Cardiovascular AI Investments: A Framework for VCs

For investors working through the burgeoning healthcare AI market, particularly in cardiology, the following benchmarks are essential:

• Regulatory Clearances: Prioritize companies with multiple FDA 510(k) or De Novo clearances. These are not mere checkboxes. They represent significant investments in clinical validation and de-risk market entry. A Breakthrough Device Designation is an even stronger signal of novel, impactful technology.
• Clinical Trial Publication Counts: Look for a strong portfolio of peer-reviewed publications in reputable medical journals. The quality and rigor of these studies (e.g., prospective, multi-center trials) are more important than sheer volume. This evidence directly supports claims of clinical utility and efficacy.
• Reimbursement Pathway Clarity: Companies that have secured Category I CPT codes or are actively pursuing NTAP eligibility demonstrate a clear understanding of the commercialization field. Without a viable reimbursement strategy, even validated AI solutions will struggle to achieve widespread adoption.
• Data Moat & Algorithmic Governance: Assess the proprietary nature and scale of their training datasets. Does the company have a strategy for managing algorithmic drift? Does it adhere to GMLP principles and have a PCCP in place, particularly for adaptive AI models?
• Integration into Workflow: Does the AI smoothly integrate into existing clinical workflows, or does it require significant changes? The most innovative solutions enhance, rather than disrupt, clinical practice.

Companies that excel across these dimensions are building more than just innovative algorithms. They are constructing a formidable patent thicket and a defensible competitive position. They are not merely “AI-native”. They are “evidence-native.”

Methodology Note: Regulatory and Clinical Database Analysis

Our assessment is rooted in a systematic review of publicly available regulatory and clinical data. This includes:

1. FDA 510(k) and De Novo Databases: Direct interrogation of the FDA’s medical device databases to verify clearances, predicate devices, and indications for use.
2. ClinicalTrials.gov and other Trial Registries: Analysis of registered clinical trials, including study design, endpoints, and status, to gauge the rigor of validation efforts.
3. PubMed and other Medical Literature Databases: Review of peer-reviewed publications associated with each company’s technology, focusing on study quality and clinical outcomes.
4. Patent Databases: Examination of patent filings to understand intellectual property protection strategies.

This rigorous, data-driven approach allows us to move beyond anecdotal claims of innovation and provide a quantitative, authoritative perspective on which cardiovascular AI companies are truly poised for long-term success. The future of healthcare AI investments belongs to those who understand that clinical evidence is not a barrier to innovation, but its ultimate validation.